| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/23/2005 | CN1585767A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585766A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585764A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585650A 可食性薄膜 Edible film |
| 02/23/2005 | CN1585646A Strontium compound for treatment of sub-dermal soft tissue pain |
| 02/23/2005 | CN1585642A Pharmaceutical compositions containing 3, 4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 02/23/2005 | CN1585635A 2-(4-isobutylphenyl) propionic acid medicinal composition |
| 02/23/2005 | CN1585632A Coated capsule |
| 02/23/2005 | CN1585631A Process for preparing quick dissolving, high loading ribavirin compositions |
| 02/23/2005 | CN1585627A Microfabricated nanopore device for sustained release of therapeutic agent |
| 02/23/2005 | CN1583762A Axial substituted phthalocyanine compound, its preparation and application in optical kinetic treatment |
| 02/23/2005 | CN1583176A Wax composition for sealing medicine pills |
| 02/23/2005 | CN1583175A Skin targeting medicinal composition and its preparation and use |
| 02/23/2005 | CN1583174A Long-term injection containing ethylcellulose and fatty acid ester |
| 02/23/2005 | CN1583139A Preparation of dragon's blood and phospholipin composition |
| 02/23/2005 | CN1582927A Oral disintegrants of nimodipine and their preparation |
| 02/23/2005 | CN1582922A Sustained releasing preparation of vilamin C and its preparing method |
| 02/23/2005 | CN1582902A Medicinal transferring system for intracephalic transference of medicine |
| 02/23/2005 | CN1582900A Lipid composition for providing genes and polypeptides with medicines by mucosa and its preparation |
| 02/23/2005 | CN1190189C Transdermal therapeutic system containing pergolide |
| 02/23/2005 | CN1190187C Solid state solutions and dispersions of poorly water soluble drugs |
| 02/23/2005 | CN1190186C Carbohydrate medical solution and sulphite stabilisator in multiple compartment container and use thereof |
| 02/22/2005 | US6858736 Core of sorbitol and the end groups can be derivatized; use as biodegradable polymeric hydrogel for surgical or biological implants or as biosealants |
| 02/22/2005 | US6858724 Used as anti-tumor agents and/or anti-HIV agents having immunostimulate activities; inversion of OR2 to OR1 in glucopyranose derivtives (R1= H or acetyl, R2= a leaving group such as tosylate, trifluoromesylate or methanesulfonate |
| 02/22/2005 | US6858723 Amphiphile cyclodextrins, preparation and use thereof for solubilizing organized systems and incorporating hydrophobic molecules |
| 02/22/2005 | US6858673 Biocompatibility, may be used for various cosmetics, drugs |
| 02/22/2005 | US6858596 Aqueous suspension of Fluticasone furoate; respiratory tract disorders; asthma, COPD; antiinflammatory, antiallergen; nasal inhaler |
| 02/22/2005 | US6858584 For therapy of bacterial disease in a mammal; side effect reduction |
| 02/22/2005 | US6858582 Composition containing porous microparticle impregnated with biologically-active compound for treatment of infection |
| 02/22/2005 | US6858581 Peptides which are modified with at least one hydrocarbyl group and which possess antimicrobial acitivity |
| 02/22/2005 | US6858580 Immobilization of drugs |
| 02/22/2005 | US6858409 Identifying nucleotide sequences which code modulator for treating arthritis, inflammatory bowel, sepsis and adult respiratory distress diseases; immunosuppressant |
| 02/22/2005 | US6858231 Agglomerate of microcrystalline cellulose particles and silicon dioxide particles, preferably colloidal silicon dioxide. |
| 02/22/2005 | US6858229 In situ forming hydrogels |
| 02/22/2005 | US6858228 Compression of drug and adjuvant |
| 02/22/2005 | US6858227 Useful in solubilizing lipophilic and relatively water-insoluble compounds; cosmetics, drugs |
| 02/22/2005 | US6858226 Fusogenic lipids and vesicles |
| 02/22/2005 | US6858225 A mixture of lipids containing a protonatable or deprotonatable lipid, such as polyoxyethylene glycol or polyamide oligomer modified lipid, or amino lipid is combined with a buffered aqueous solution of a charged drug |
| 02/22/2005 | US6858222 Fabrication of drug loaded biodegradable polymer fibers |
| 02/22/2005 | US6858216 Treatment of keratin fibers and skin. |
| 02/22/2005 | US6858214 Use of nanoscalar water-soluble β-(1,3) glucans |
| 02/22/2005 | US6858210 For inducing tolerance in an individual; bind to anti-cardiolipin ( beta 2GPI-dependent antiphospholipid) |
| 02/22/2005 | US6858206 Methods for treating diseases caused by deficiencies of recombinant alpha-L-iduronidase |
| 02/22/2005 | US6858203 Treating of hyperphosphatemia by ingesting a ion exchanging resin comprising an allyl addition polymer having an amine salt or quaternary amine functional group; side effect reduction |
| 02/22/2005 | US6858202 Detergent compositions with enhanced depositing, conditioning and softness capabilities |
| 02/22/2005 | US6858166 Enteric coatings for drugs; sustained rlease |
| 02/22/2005 | US6858018 Iontophoretic devices |
| 02/22/2005 | CA2184581C Improved dnase liquid solutions |
| 02/22/2005 | CA2106423C Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| 02/22/2005 | CA2093022C Targeted immunostimulation with bispecific reagents |
| 02/21/2005 | CA2477901A1 Cyanoacrylate compositions containing anti-microbial agent |
| 02/17/2005 | WO2005015158A2 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 02/17/2005 | WO2005014823A2 Targeted carrier fusions for delivery of chemotherapeutic agents |
| 02/17/2005 | WO2005014777A2 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 02/17/2005 | WO2005014655A2 Conjugates of hydroxyalkyl starch and a protein |
| 02/17/2005 | WO2005014071A1 Methods and devices for the treatment of intervertebral discs |
| 02/17/2005 | WO2005014050A2 Conjugates of hydroxyalkyl starch and g-csf |
| 02/17/2005 | WO2005014048A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 02/17/2005 | WO2005014047A1 Bioadhesive gel based on hydroxyethylcellulose |
| 02/17/2005 | WO2005014037A2 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | WO2005014034A1 Stabilized formulation of parathyroid hormone |
| 02/17/2005 | WO2005014031A1 Use of calcitonin in osteoarthritis |
| 02/17/2005 | WO2005014024A2 Conjugates of a polymer and a protein linked by an oxime linking group |
| 02/17/2005 | WO2005014013A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | WO2005014010A1 Pharmaceutical composition comprising gemcitabine and cyclodextrines |
| 02/17/2005 | WO2005014009A1 Glycyrrhizin high-concentration preparation |
| 02/17/2005 | WO2005013991A1 Dry syrup containing loratadine |
| 02/17/2005 | WO2005013987A1 Fexofenadine composition and process for preparing |
| 02/17/2005 | WO2005013973A1 Semi-solid systems containing azetidine derivatives |
| 02/17/2005 | WO2005013972A1 Emulsifying systems containing azetidine derivatives |
| 02/17/2005 | WO2005013964A1 Pharmaceutical preparation containing nateglinide |
| 02/17/2005 | WO2005013959A1 Veterinary aqueous injectable suspensions containing florfenicol |
| 02/17/2005 | WO2005013955A2 Topical composition comprising terbinafine and hydrocortisone |
| 02/17/2005 | WO2005013943A1 Hydrophilic adhesive compositions for delivery of herbal medicines |
| 02/17/2005 | WO2005013938A1 Process for producing drug ultramicroparticle and apparatus therefor |
| 02/17/2005 | WO2005013934A2 Taste-masked composition of cationic exchange resin |
| 02/17/2005 | WO2005013933A1 Mucoadhesive composition comprising polyacrylate and chemoattractant |
| 02/17/2005 | WO2005013897A2 Magnetic nanoparticle compositions, and methods related thereto |
| 02/17/2005 | WO2005013896A2 Programmed immune responses using a vaccination node |
| 02/17/2005 | WO2004104493A3 Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| 02/17/2005 | WO2004099135A3 Hiv prodrugs cleavable by cd26 |
| 02/17/2005 | WO2004091592A3 Methods and compositions to treat myocardial conditions |
| 02/17/2005 | WO2004091551A3 Anti-tumor vasculature effects of human serum albumin derivatives |
| 02/17/2005 | WO2004091280A3 Pharmaceutical compositions |
| 02/17/2005 | WO2004072249A3 Polyvinylethers for delivery of polynucleotides to mammalian cells |
| 02/17/2005 | WO2004056338A3 Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
| 02/17/2005 | WO2004052401A3 Compositions and methods of delivery of pharmacological agents |
| 02/17/2005 | WO2003082019A9 Peptides with anti-hypertensive properties |
| 02/17/2005 | WO2003070910A3 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/17/2005 | US20050038505 Drug-delivery endovascular stent and method of forming the same |
| 02/17/2005 | US20050038239 Locked nucleic acid conjugate for use in treatment of cell proliferative disorders |
| 02/17/2005 | US20050038121 Abuse resistant lysine amphetamine compounds |
| 02/17/2005 | US20050038118 Treatment |
| 02/17/2005 | US20050038111 4'-cyano- alpha ', alpha ', alpha '-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide; anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole); preventing side effect; bioavailability; storage stability; prostate cancer |
| 02/17/2005 | US20050038039 Formulations |
| 02/17/2005 | US20050038022 Using a benzimidazole carbamate compound in lipid carrier; antitumor agents |
| 02/17/2005 | US20050037996 Controlling temperature and pH while complexing |
| 02/17/2005 | US20050037994 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same |
| 02/17/2005 | US20050037993 Bulking agents as satiety agents |
| 02/17/2005 | US20050037974 E-Ca R Cb-A, in which E is a diagnostic agent, R is a reactive group, Cb and Ca are optional first and second connecting groups, and A is an affinity group that is any molecule or part of a molecule possessing specific binding determinants for a target molecule |